Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748501 | 0.87 | CTNNB1 (0.54) | BRD4CTNNB1TTRSMN1; SMN2CYP3A4 | |
| SCHEMBL31633492 | 0.86 | ALDH1A1 (0.46) | CYP3A4TP53MAPTPDE4AKDR | |
| SCHEMBL3223768 | 0.84 | HSD17B10 (0.52) | BRD4CTNNB1TSPOTTRSMN1; SMN2 | |
| SCHEMBL27482498 | 0.83 | BRD4 (0.49) | BRD4CTNNB1TTRSMN1; SMN2CYP3A4 | |
| SCHEMBL5217469 | 0.81 | ALDH1A1 (0.50) | BRD4CTNNB1SMN1; SMN2CYP3A4LMNA | |
| SCHEMBL2750155 | 0.81 | ALDH1A1 (0.51) | BRD4CTNNB1SMN1; SMN2CYP3A4LMNA | |
| SCHEMBL9948495 | 0.81 | CYP1A2 (0.54) | CTNNB1TSPOSMN1; SMN2CYP3A4LMNA | |
| SCHEMBL19524223 | 0.81 | SCN8A (0.56) | CTNNB1TSPOTTRSMN1; SMN2LMNA | |
| SCHEMBL3179214 | 0.79 | CTNNB1 (0.67) | CTNNB1TSPOSMN1; SMN2LMNATP53 | |
| SCHEMBL29679671 | 0.79 | CTNNB1 (0.67) | CTNNB1TSPOSMN1; SMN2LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | BRD4 864/4885CTNNB1 3011/4885TSPO 4625/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | BRD4 864/4885CTNNB1 3011/4885TSPO 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.